About NeuroPace
NeuroPace is a company based in United States founded in 1997. NeuroPace has raised $263.56 million across 8 funding rounds from investors including Kleiner Perkins, Orbimed and Revelation Partners. The company has 184 employees. NeuroPace offers products and services including RNS System. NeuroPace operates in a competitive market with competitors including Cadence Neuroscience, Engage Therapeutics, Cyberonics, CerboMed and NightWatch, among others.
- Annual Revenue$99.99 M (USD)25.13as on Dec 31, 2025
- Net Profit-$21.46 M (USD)20.91as on Dec 31, 2025
- EBITDA-$14.39 M (USD)27.7as on Dec 31, 2025
- Total Equity Funding$263.56M (USD)
in 8 rounds
- Latest Funding Round$69.39M (USD), Series E
Aug 2020
- InvestorsKleiner Perkins
& 11 more
- Employee Count184
Products & Services of NeuroPace
NeuroPace offers a comprehensive portfolio of products and services, including RNS System.
Delivers personalized therapy to reduce seizures in drug-resistant epilepsy patients.
Apps and channels of NeuroPace
its YouTube channel NeuroPace RNS System for Epilepsy has 974 subscribers and 30 videos.
Videos from NeuroPace
The most watched videos on NeuroPace's YouTube channel, NeuroPace RNS System for Epilepsy (974 subscribers). Click a video to play it here.
More on NeuroPace RNS System for Epilepsy.
Funding Insights of NeuroPace
NeuroPace has successfully raised a total of $263.56M across 8 strategic funding rounds. The most recent funding activity was a Series E round of $69.39 million completed in August 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $263.56M
- Total Rounds 8
- Last Round Series E — $69.39M
- First Round $2.5M
(Sep 2003)
- Investors Count 12
All 8 funding rounds of NeuroPace with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2020 | $69.39M | Series E | – | Accelmed | |
| Sep 2016 | $74M | Series E | – | Orbimed | – |
| Mar 2014 | $2.5M | Grant | – | – | |
| Jul 2013 | $18.05M | Series D | – | – | – |
| Aug 2011 | $49.13M | Series C | – | New Enterprise Associates, InterWest Partners | – |
| Jun 2008 | $23M | Series B | – | – | |
| Jun 2005 | $30M | Series A | – | Domain Associates, InterWest Partners | – |
| Sep 2003 | $2.5M | Grant | – | – |
12 investors in total: 12 institutional.
Investors in NeuroPace
NeuroPace has secured backing from 12 investors, including venture fund and institutional investors. Prominent investors backing the company include Kleiner Perkins, Orbimed and Revelation Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
- | – | accelmed.com | - | |
- | – | soleuscapital.com | - | |
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
Venture capital investments are offered to startups by NEA. | – | nea.com | Menlo Park, United States | |
Early-stage investing in IT and healthcare ventures. | – | interwest.com | - | |
Venture capital firm backed by Johnson & Johnson | – | jnjinnovation.com/jjdc | Cambridge, United States | |
Investments are made in US life sciences and energy companies. | – | technologypartners.com | Palo Alto, United States | |
Life sciences sector focused VC firm funding companies in the US | – | medven.com | Emeryville, United States | |
Life science & tech focused VC firm investing in the US | – | domainvc.com | Princeton, United States | |
Venture capital firm investing in early-stage tech startups | 1972 | kleinerperkins.com | Menlo Park, United States |
Investor details for NeuroPace
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of NeuroPace
43 people are tracked at NeuroPace (18 in leadership, 6 in board & advisors, 19 in team); the tracked headcount is 184.
| Name | Role | Group |
|---|---|---|
Dylan St. John | Chief Of Operations & Development | Leadership |
Cairn Seale | VP, Clinical Research | Leadership |
Brett Wingeier | VP, Research & Development | Leadership |
Katie Keller | VP, Marketing | Leadership |
Julie H. | Vp, Controller | Leadership |
Rebecca Kuhn | CFO & VP, Finance & Administration | Leadership |
Joel D. Becker | CEO & Board Member | Leadership |
Irene Thomas | VP, Human Resources | Leadership |
Stacey Ellul | VP, Quality & Regulatory Affairs | Leadership |
Scott Schaper | Head Of Investor Relations | Leadership |
Martha Morrell | Chief Medical Officer | Leadership |
Amy Treadwell | Vice President Human Resources | Leadership |
Mark Breeden | Director Of Patient And Device Data Strategy | Leadership |
Eric Frech | Director Of Software Development | Leadership |
David Mar | Director Of Manufacturing Operations | Leadership |
Cindy Heintzelman | Sr. Director, Quality Assurance | Leadership |
Rohit C. Reddy | Director, Upstream & Strategic Marketing | Leadership |
Jatin Sharma | Director Of Ai/ml | Leadership |
Renee Ryan | Director | Board & advisors |
Uri Geiger | Director | Board & advisors |
23 more people are available in the full profile.
Complete people profiles for NeuroPace
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of NeuroPace
NeuroPace is a publicly listed company on the NASDAQ with ticker symbol NPCE in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date22 Apr 2021
- Listed onNASDAQ: NPCE
- Listed entityNeuropace, Inc.
- Exchange sectorHealth technology
- ISINUS6412881053
- Share price$12.39 (-2.9% on the day) · 2026-10-08
- Market capitalisation$425.3M
- EPS (diluted, trailing year)$-0.57
- Volume (last session)142,582
Financials of NeuroPace
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $100.0M | -$21.5M | -$14.4M |
| 2024 | $79.9M | -$27.1M | -$19.9M |
| 2023 | $65.4M | -$33.0M | -$25.6M |
| 2022 | $45.5M | -$47.1M | -$37.8M |
| 2021 | $45.2M | -$36.1M | -$23.4M |
Detailed financial statements for NeuroPace
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of NeuroPace
4 dated milestones of NeuroPace across 24 years, from founding to its latest funding, stage changes and deals.
- Founded NeuroPace is founded.
- Funding First funding round of $2.5M.
- Funding Latest funding round, Series E, of $69.4M.
- IPO Lists on the stock exchange (IPO).
Competitors of NeuroPace
NeuroPace operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Cadence Neuroscience, Engage Therapeutics, Cyberonics, CerboMed and NightWatch, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| cadenceneuro.com | 2016 | Redmond, United States | $41.03M | – | Medical devices for treating neurological disorders like epilepsy are developed. | |
| engagetherapeutics.com | 2017 | Summit, United States | $30.6M | – | Inhaled drug-device combo as rescue treatment for uncontrolled epileptic seizures | |
| cyberonics.com | 1987 | Houston, United States | – | 660 | Vagus nerve stimulation therapy is developed for epilepsy and depression. | |
| cerbomed.de | 2005 | Erlangen, Germany | $2.6M | – | Neuro-therapy solutions are developed for drug-resistant epilepsies and disorders. | |
| nightwatchepilepsy.com | 2013 | Leiden, Netherlands | – | – | Wearable armbands for detecting epileptic seizures during sleep are offered. | |
| precisis.de | 2002 | Heidelberg, Germany | – | 14 | Devices and tools for neurological surgery are developed. | |
| neurolinkmedical.com | 2007 | San Antonio, United States | $3.88M | – | Develops drug-device combinations for epilepsy treatment. | |
| squalusmed.com | 2019 | Caesarea, Israel | – | – | Image-guided laser platforms are developed for epilepsy treatment. |
Detailed competitors of NeuroPace
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of NeuroPace
The website of NeuroPace (neuropace.com) receives about 27.7K visits a month.
- Monthly visits27.7K
▲ 41.8% vs previous month
Websites whose visitors overlap most with NeuroPace. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
epilepsy.com | epilepsy.com | 100% | – | #90,757 | – |
| medtronic.com | 87% | 2.6M | #22,622 | View details | |
| neurosigma.com | 76% | 1.9K | #9,554,781 | View details | |
| intersectent.com | 65% | – | – | View details | |
| adamaspharma.com | 65% | – | – | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 11 similar websites and full traffic analytics for NeuroPace
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 11 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Neuropace
Complete news archive for NeuroPace
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to NeuroPace
10 companies that operate in the same segment as NeuroPace (Neurology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 | |
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
MR-interfaced ultrasound devices for cancer and neurology treatments are provided. | 1999 | Tirat Carmel, Haifa District, Israel | USD 574.2 M | – | – | |
AI-driven drug discovery platform for neurological diseases based on patients biomarkers | 2019 | San Francisco, California, United States | USD 144.72 M | – | 76 | |
Small molecule drugs for rare diseases are developed. | 1998 | South Plainfield, New Jersey, United States | USD 248.1 M | USD 1.73 B | 939 | |
Developer of small molecule therapeutics for endocrine and CNS disorders | 1992 | San Diego, California, United States | USD 10 M | USD 2.86 B | 1,800 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | – | 100 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about NeuroPace
NeuroPace was founded in 1997 and raised its 1st funding round 6 years after it was founded.
NeuroPace is headquartered in United States.
NeuroPace is a funded company, having raised a total of $263.56M across 8 funding rounds to date. The company's 1st funding round was a Grant of $2.5M, raised on Sep 2003.
NeuroPace has 184 employees.
Annual revenue of NeuroPace is $99.99M as on Dec 31, 2025.
Founded in 1997 in the United States, NeuroPace operates in the medical device sector, focusing on neurostimulation technologies. Implantable systems are designed to detect and respond to abnormal brain activity in adults with drug-resistant focal epilepsy, delivering targeted stimulation to reduce seizures. EEG data is collected and shared to support clinical monitoring and patient management. Resources, including support services, are provided to patients and healthcare professionals for ongoing care.
NeuroPace's top competitors include Engage Therapeutics, Cyberonics and Cadence Neuroscience.
NeuroPace offers RNS System.
Yes, NeuroPace is publicly traded on NASDAQ under the ticker symbol NPCE.
NeuroPace has 12 investors. Key investors include Kleiner Perkins, Orbimed, Revelation Partners, Accelmed, and Soleus Capital.
NeuroPace operates through Neuropace, Inc..